Search

Displaying results 3531 - 3540 of 5506 in total
  1. Drug

    CYT006-AngQb

    go.drugbank.com/drugs/DB05739
    Investigational

    It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination. … It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure

  2. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells.

  3. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous c...

  4. Drug

    Gepotidacin

    go.drugbank.com/drugs/DB12134
    ApprovedInvestigational

    Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV. Its target is similar to that of fluoroquinolone antibacterials - e.g. ciprofloxacin - while being structurally and p...

  5. Drug

    V1003

    go.drugbank.com/drugs/DB05046
    Experimental

    and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both prior to discharge from hospital and at

  6. Drug

    Pyridoxal

    go.drugbank.com/drugs/DB00147
    ExperimentalNutraceutical

    The 4-carboxyaldehyde form of vitamin B 6 which is converted to pyridoxal phosphate which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. [PubChem]

  7. Drug

    NOX-700

    go.drugbank.com/drugs/DB05464
    Experimental

    It has since been found that oxidative signaling of the redox-sensitive transcription factor, NF-κB, and inhibiting protein glycation are responsible for the drug's therapeutic effects.

  8. Drug

    Scorpion (centruroides) immune Fab2 antivenin (equine)

    go.drugbank.com/drugs/DB13905
    Approved

    It was approved by FDA in 2011 and is marketed under the name Anascorp [L2196]. Anascorp is produced from equine IgG antibodies. … It is intravenously administered patients with clinical signs of scorpion envenomation so that the Fab fragments bind to the toxins and limit systemic toxicity.

  9. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    [L31863] Umbralisib inhibits casein kinase, a primary regulator of protein translation, kinase-1ε, distinguishing it from other lymphoma treatments. … It was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.

  10. Drug

    Meningococcal polysaccharide vaccine group A

    go.drugbank.com/drugs/DB13889
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.